296 related articles for article (PubMed ID: 21685240)
1. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
2. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
3. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
4. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
5. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
McLaughlin PJ; Rogosnitzky M; Zagon IS
Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
[TBL] [Abstract][Full Text] [Related]
9. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
10. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
11. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460
[TBL] [Abstract][Full Text] [Related]
12. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
[TBL] [Abstract][Full Text] [Related]
13. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
14. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Rahn KA; McLaughlin PJ; Zagon IS
Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
[TBL] [Abstract][Full Text] [Related]
15. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
19. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
20. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.
Zagon IS; Rahn KA; Turel AP; McLaughlin PJ
Exp Biol Med (Maywood); 2009 Nov; 234(11):1383-92. PubMed ID: 19855075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]